中国麻风皮肤病杂志 ›› 2021, Vol. 37 ›› Issue (4): 252-255.doi: 10.12144/zgmfskin202104252

• 综述 • 上一篇    下一篇

梅毒螺旋体耐抗生素研究进展

裴晓燕,田洪青   

  1. 山东第一医科大学附属皮肤病医院（山东省皮肤病医院，山东省皮肤病性病防治研究所），济南，250022
  • 出版日期:2021-04-15 发布日期:2021-04-07
  • 通讯作者: 田洪青，E-mail: tianhq2006@126.com

Updata of antibiotic resistance of Treponema pallidum

PEI Xiaoyan, TIAN Hongqing   

  1. Shandong Provincial Hospital for Skin Disease & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University, Jinan 250022, China
  • Online:2021-04-15 Published:2021-04-07
  • Contact: TIAN Hongqing, E-mail: tianhq2006@126.com

PDF (PC)

445

摘要： 青霉素一直是治疗梅毒的一线用药，常用替代药物有第三代头孢菌素、大环内酯类和四环素类抗生素。对大环内酯类耐药的梅毒螺旋体(Tp)菌株已在全球多个地区流行，近年也有四环素类治疗梅毒失败的例子，但其耐药情况尚不普遍。本文将对Tp耐药情况、已报道的耐药突变和潜在的耐药分子机制进行综述。

关键词: 梅毒, 梅毒螺旋体, 抗生素, 耐药

Abstract: Penicillin has always been the first-line medication for the treatment of syphilis. The substitutes include the third generation cephalosporins, macrolides and tetracyclines. Macrolide-resistant Treponema pallidum (Tp) strains have been prevalent in many regions of the world. In recent years, cases of failure in the treatment of syphilis with tetracyclines have been reported, but the tetracyclines resistance is not widespread. The updata of prevalence of antibiotic resistance of Tp, the reported mutations and the potential molecular mechanism of antibiotic resistance of Tp is reviewed in this paper.

Key words: syphilis, Treponema pallidum, antibiotics, antibiotic resistance